Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BeiGene Australia Pty Ltd
Scientific Title
A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations Who Have Received No Previous Treatment for Metastatic Disease